BioLineRx (NASDAQ:BLRX – Get Free Report) announced its earnings results on Tuesday. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.04), Zacks reports. The company had revenue of $0.48 million for the quarter, compared to the consensus estimate of $0.36 million. BioLineRx had a negative return on equity of 5.61% and a negative net margin of 99.58%.
BioLineRx Trading Up 6.6%
Shares of BioLineRx stock opened at $3.37 on Thursday. The firm has a market capitalization of $14.66 million, a PE ratio of -19.82 and a beta of 1.42. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.95 and a quick ratio of 1.78. The company’s fifty day moving average price is $2.61 and its two-hundred day moving average price is $2.88. BioLineRx has a 52-week low of $2.15 and a 52-week high of $7.77.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of BioLineRx in a report on Monday, April 20th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, BioLineRx currently has a consensus rating of “Moderate Buy”.
About BioLineRx
BioLineRx (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company that discovers and develops novel small-molecule therapies to address unmet medical needs. The company focuses on identifying promising drug candidates through licensing and collaboration agreements with academic institutions and biotech innovators, then advancing these candidates through preclinical and clinical development stages. BioLineRx’s pipeline spans oncology, immunology and inflammatory diseases, central nervous system disorders and pain management.
Among its clinical programs, BioLineRx is advancing targeted cancer therapies designed to improve outcomes for patients with difficult-to-treat tumors.
Read More
- Five stocks we like better than BioLineRx
- Bath & Body Works Stock Surged Despite Falling Sales—Here’s Why
- Dick’s Sporting Goods Isn’t Done Winning Yet
- Abercrombie Rallies as Strong Q1 Earnings Extend Winning Streak
- TeraWulf Bets on Power Infrastructure to Lead AI Build-Out
Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.
